In fact, circulating autologous CD14+ cells are the progenitor of resident NLCs and the baseline upregulation of Siglec‐10 might reflect the M2‐like immunosuppressive profile of NLCs within TME, where they interact with CD24+ cancer cells, receiving anti‐phagocytic stimuli.7, 8. Here, SIGLEC10 is linked to cancer.